AxoGen, Inc.

NasdaqCM AXGN

AxoGen, Inc. Market Capitalization on January 14, 2025: USD 802.71 M

AxoGen, Inc. Market Capitalization is USD 802.71 M on January 14, 2025, a 132.88% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • AxoGen, Inc. 52-week high Market Capitalization is USD 803.15 M on January 13, 2025, which is 0.05% above the current Market Capitalization.
  • AxoGen, Inc. 52-week low Market Capitalization is USD 245.84 M on May 06, 2024, which is -69.37% below the current Market Capitalization.
  • AxoGen, Inc. average Market Capitalization for the last 52 weeks is USD 462.25 M.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
NasdaqCM: AXGN

AxoGen, Inc.

CEO Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A.
IPO Date Dec. 17, 1986
Location United States
Headquarters 13631 Progress Boulevard
Employees 426
Sector Health Care
Industries
Description

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Similar companies

SRDX

Surmodics, Inc.

USD 35.55

-0.81%

AORT

Artivion, Inc.

USD 29.68

1.16%

CNMD

CONMED Corporation

USD 67.79

-2.46%

LIVN

LivaNova PLC

USD 47.63

0.66%

SIBN

SI-BONE, Inc.

USD 15.70

-3.27%

ELMD

Electromed, Inc.

USD 31.05

1.90%

ITGR

Integer Holdings Corporation

USD 138.83

2.72%

KIDS

OrthoPediatrics Corp.

USD 23.55

-5.80%

RXST

RxSight, Inc.

USD 30.08

-2.08%

TMCI

Treace Medical Concepts, Inc.

USD 8.01

-4.19%

LUNG

Pulmonx Corporation

USD 6.84

-2.98%

FNA

Paragon 28, Inc.

USD 10.28

-4.28%

OFIX

Orthofix Medical Inc.

USD 17.51

0.81%

ANIK

Anika Therapeutics, Inc.

USD 15.58

-2.14%

StockViz Staff

January 15, 2025

Any question? Send us an email